Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis

Medicine (United States)

Volumn 95, Issue 37, 2016, Pages

  Fukui, Shoichi ^a   Iwamoto, Naoki ^a   Umeda, Masataka ^a   Nishino, Ayako ^a   Nakashima, Yoshikazu ^a   Koga, Tomohiro ^a   Kawashiri, Shin Ya ^a,b   Ichinose, Kunihiro ^a   Hirai, Yasuko ^a   Tamai, Mami ^a   Nakamura, Hideki ^a   Origuchi, Tomoki ^a   Sato, Shuntaro ^a   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Complement; Diffuse alveolar hemorrhage; Hypocomplementemia; Prognosis; Relapse; Thrombotic microangiopathy

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS; ANTIINFLAMMATORY AGENT; COMPLEMENT;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPOCOMPLEMENTEMIA; IMMUNE COMPLEX DEPOSITION; INCIDENCE; KIDNEY BIOPSY; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SKIN DEFECT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COMPLICATION; DEFICIENCY; EPIDEMIOLOGY; JAPAN; MIDDLE AGED; MORTALITY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES;

EID: 84991696423     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004871     Document Type: Article

References (29)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-1.
2. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 2004;65:2145-52.
3. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014;10:463-73.
4. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64.
5. van Timmeren MM, van der Veen BS, Stegeman CA, et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol 2010;21:1103-14.
6. Molad Y, Tovar A, Ofer-Shiber S. Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract 2014;126:67-74.
7. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
10. Kostianovsky A, Hauser T, Pagnoux C, et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012;30:S77-82.
11. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323-35.
12. JSN and MHLW Clinical Practice Guidelines for RPGN 2014. Nihon Jinzo Gakkai Shi 2015;57:139-232.
13. Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessmentin systemic vasculitis. Postgrad Med J 2008;84:143-52.
14. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
15. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-10.
16. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010;34:J276-286.
17. Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009;29:282-91.
18. Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-98.
19. Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25:225-31.
20. Hirayama K, Kobayashi M, Usui J, et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant 2015;30(Suppl 1):i83-93.
21. West S, Arulkumaran N, Ind PW, et al. Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med 2013;52:5-13.
22. Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest 1996;110: 1305-16.
23. Fujimoto K, Imura J, Atsumi H, et al. Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese. Clin Exp Nephrol 2015;19:804-14.
24. Yumura W, Kobayashi S, Suka M, et al. Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis. Mod Rheumatol 2014;24:304-9.
25. Chen SF, Wang H, Huang YM, et al. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin J Am Soc Nephrol 2015;10:750-8.
26. Manenti L, Gnappi E, Vaglio A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation 2013;28: 2246-59.
27. Sada KE, Yamamura M, Harigai M, et al. Classification and character-istics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 2014;16:R101.
28. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
29. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015; 14:857-77.